TOP TIERMARKET NEWSWIRE
Movers explained · 2026-11-18

Archived explainer. For the current picture see today's ERAS page.

Why Is ERASCA INC (ERAS) Stock Down Today?

By the Top Tier Newswire AI Desk · November 18, 2026 at 12:14 AM ET · reviewed against 7 wire stories

ERASCA INC (ERAS) is down -8.07% in the latest session. Our newswire has captured 7 stories on ERAS across 5 sources in the last 36 hours, with AI sentiment reading bullish (avg 59/100).

Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.

Erasca (ERAS) shares fell 8.07% to $13.89, a move driven by the announcement of a clinical collaboration with Bristol Myers Squibb. The agreement involves evaluating ERAS-0015 in a Phase 1/2 trial for MTAP-deleted pancreatic cancer, with Bristol Myers Squibb sponsoring the study alongside the PRMT5 inhibitor navlimetostat.

What Happened

The primary catalyst for the session was the disclosure of the partnership with Bristol Myers Squibb. Under the terms of the agreement, ERAS-0015 will be tested in combination with navlimetostat in a clinical study targeting pancreatic cancer. This development follows a period of heightened analyst activity, where Leerink Partners initiated coverage of the stock with an Outperform rating and a price target of $35. The firm’s initiation was part of a broader wave of seven stories from five sources published within the last 36 hours. Additionally, Erasca announced it will host a virtual investor event on November 20, 2026, to highlight clinical momentum across its RAS-targeting franchise.

What The Data Shows

The stock’s valuation context is defined by a market capitalization of $5.5 billion and a trailing twelve-month earnings per share of negative $0.99. The 52-week trading range spans from $2.50 to $24.28. Over the last eight sessions, the stock had already declined 5.0%, moving from $14.78 to $14.04 before today’s drop. Unusual options activity in the last 36 hours showed a single notable print with $1.1 million in put premium and no call premium, indicating a bearish directional bet. The 52-week tape recorded one fresh high and 40 fresh lows on November 17, 2026. Retail sentiment has improved, with the 7-day average trending higher than the 30-day average, though the immediate price action remains negative.

What To Watch

Investors will look to the virtual investor event scheduled for November 20, 2026, for further details on the company’s clinical pipeline. The market will also monitor how the stock reacts to the new Bristol Myers Squibb collaboration and the broader analyst coverage initiated by Leerink Partners.

AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.

ERAS by the numbers

Last: $13.89Session: -8.07%7 sessions: -5.01%Coverage: 7 stories / 5 sourcesAI sentiment: 59/100 (bullish)Mkt cap: $5.5B52w: $2.50 to $24.28
ERAS · Nov 18 session (5-min) · -2.30% vs prior close · updated 8:53 PM ET
$12.92$13.82$14.72prev close $13.89$13.577:00 AM10:00 AM1:00 PM4:00 PM7:00 PM7:00 AM · $14.017:45 AM · $14.038:35 AM · $14.408:40 AM · $14.639:00 AM · $14.579:25 AM · $13.919:30 AM · $13.789:35 AM · $13.819:40 AM · $13.979:45 AM · $13.609:50 AM · $13.509:55 AM · $13.5710:00 AM · $13.4710:05 AM · $13.6210:10 AM · $13.5310:15 AM · $13.5410:20 AM · $13.6010:25 AM · $13.5410:30 AM · $13.3510:35 AM · $13.2210:40 AM · $13.2010:45 AM · $13.1710:50 AM · $13.1410:55 AM · $13.2411:00 AM · $13.2111:05 AM · $13.1511:10 AM · $13.2311:15 AM · $13.1511:20 AM · $13.1311:25 AM · $13.2211:30 AM · $13.2211:35 AM · $13.1211:40 AM · $13.1311:45 AM · $13.1111:50 AM · $13.1211:55 AM · $13.1312:00 PM · $13.1112:05 PM · $13.0612:10 PM · $13.2612:15 PM · $13.4412:20 PM · $13.4312:25 PM · $13.3312:30 PM · $13.3212:35 PM · $13.2712:40 PM · $13.2212:45 PM · $13.2712:50 PM · $13.3012:55 PM · $13.201:00 PM · $13.221:05 PM · $13.251:10 PM · $13.261:15 PM · $13.281:20 PM · $13.321:25 PM · $13.501:30 PM · $13.541:35 PM · $13.541:40 PM · $13.511:45 PM · $13.461:50 PM · $13.451:55 PM · $13.422:00 PM · $13.372:05 PM · $13.402:10 PM · $13.402:15 PM · $13.482:20 PM · $13.532:25 PM · $13.492:30 PM · $13.472:35 PM · $13.502:40 PM · $13.462:45 PM · $13.492:50 PM · $13.532:55 PM · $13.523:00 PM · $13.623:05 PM · $13.593:10 PM · $13.613:15 PM · $13.643:20 PM · $13.623:25 PM · $13.673:30 PM · $13.553:35 PM · $13.663:40 PM · $13.613:45 PM · $13.653:50 PM · $13.793:55 PM · $13.784:00 PM · $13.104:10 PM · $13.704:20 PM · $13.764:40 PM · $13.964:50 PM · $13.765:50 PM · $13.026:00 PM · $13.577:00 PM · $13.57
AI sentiment, last 36h · averaged over 7 stories · 59/100 bullish
AI sentiment 59/100 (bullish)0 · bearish50bullish · 100

The headlines behind the move

Story flow · 6 stories on the wire, last 36h · hover or tap a dot for the headline
36h ago24h ago12h agopublishThe Fly · sentiment 63 · Erasca initiated with an Outperform at LeerinkThe Fly · 63Erasca initiated with an Outperform at LeerinkThe Fly · sentiment 64 · Leerink bullish on Erasca, initiates with an OutperformThe Fly · 64Leerink bullish on Erasca, initiates with an OutperformInvesting.com Markets · sentiment 38 · Why is Erasca stock sliding today?Investing.com Markets · 38Why is Erasca stock sliding today?GuruFocus · sentiment 63 · ERAS Initiated Coverage by Leerink Partners -- Price Target Set at $35GuruFocus · 63ERAS Initiated Coverage by Leerink Partners -- Price Target Set at $35Business Insider · sentiment 64 · Erasca Enters into Clinical Collaboration with Bristol Myers Squibb to Evaluate ERAS-0015 in Clinical Study with NavlimetostatBusiness Insider · 64Erasca Enters into Clinical Collaboration with Bristol Myers Squibb to Evaluate ERAS-0015…The Fly · sentiment 63 · Erasca announces agreement with Bristol MyersThe Fly · 63Erasca announces agreement with Bristol Myers
2d agoThe FlyBULLISH 63Product/PR

Erasca announces agreement with Bristol Myers

2d agoBusiness InsiderBULLISH 64Product/PR

Erasca Enters into Clinical Collaboration with Bristol Myers Squibb to Evaluate ERAS-0015 in Clinical Study with Navlimetostat

ERAS-0015 will be evaluated with PRMT5 inhibitor navlimetostat in MTAP-deleted pancreatic cancer in Phase 1/2 trial BMS will sponsor the clinical...

3d agoGuruFocusBULLISH 63Analyst

ERAS Initiated Coverage by Leerink Partners -- Price Target Set at $35

3d agoInvesting.com MarketsBEARISH 38General

Why is Erasca stock sliding today?

Why is Erasca stock sliding today?

3d agoThe FlyBULLISH 64Analyst

Leerink bullish on Erasca, initiates with an Outperform

3d agoThe FlyBULLISH 63Analyst

Erasca initiated with an Outperform at Leerink

4d agoGlobeNewswireBULLISH 58Product/PR

Erasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targeting Franchise

SAN DIEGO, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering,...

Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →

More on ERAS: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.

Earlier ERAS move explainers: 2026-11-18 · 2026-11-17 · 2026-11-13 · 2026-10-16 · 2026-09-23 · 2026-09-10 · 2026-09-02 · 2026-08-27 · 2026-08-26